A prospective, randomized, open-label trial comparing the safety and efficacy of trivalent live attenuated and inactivated influenza vaccines in adults 60 years of age and older

Vaccine

Volumn 29, Issue 20, 2011, Pages 3633-3639

  Forrest, Bruce D ^a   Steele, A Duncan ^b   Hiemstra, Louis ^c   Rappaport, Ruth ^a   Ambrose, Christopher S ^d   Gruber, William C ^a  

^a WYETH RESEARCH   (United States)

^b UNIVERSITY OF LIMPOPO   (South Africa)

^c Universitas Private Hospital   (South Africa)

^d MEDIMMUNE   (United States)

Author keywords

Adults; Clinical trial; Influenza; Live attenuated influenza vaccine; Trivalent inactivated influenza vaccine

Indexed keywords

GAMMA INTERFERON; INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; BRONCHOPNEUMONIA; CHILL; COHORT ANALYSIS; COMPARATIVE STUDY; COUGHING; DECREASED APPETITE; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FEVER; HEADACHE; HEMAGGLUTINATION INHIBITION; HUMAN; INCIDENCE; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; LETHARGY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NOSE CONGESTION; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; RHINITIS; RHINORRHEA; SIDE EFFECT; SORE THROAT; SOUTH AFRICA; VOMITING;

AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; DRUG EVALUATION; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNITY, CELLULAR; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; INTERFERON-GAMMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SOUTH AFRICA; VACCINATION; VACCINES, ATTENUATED; VACCINES, INACTIVATED;

EID: 79955119194     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.03.029     Document Type: Article

References (17)

1. Nichol K.L. Influenza vaccination in the elderly: impact on hospitalisation and mortality. Drugs Aging 2005, 22:495-515.
2. Data on file, MedImmune, Inc, Gaithersburg, MD.
3. Govaert T.M., Thijs C.T., Masurel N., Sprenger M.J., Dinant G.J., Knottnerus J.A. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA 1994, 272:1661-1665.
4. De Villiers P.J., Steele A.D., Hiemstra L.A., Rappaport R., Dunning A.J., Gruber W.C., et al. Efficacy and safety of a live attenuated influenza vaccine in adults 60 years of age and older. Vaccine 2009, 28:228-234.
5. The European Agency for the Evaluation of Medicinal Products. EMEA/CPMP Position statement on the use of placebo in clinical trials with regard to the revised declaration of Helsinki (EMEA/17424/01). 2011 (accessed 10.02.11). http://www.emea.europa.eu/pdfs/human/press/pos/1742401en.pdf.
6. Forrest B.D., Pride M.W., Dunning A.J., Capeding M.R., Chotpitayasunondh T., Tam J.S., et al. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol 2008, 15:1042-1053.
7. National Institute for Communicable Diseases Recommendations pertaining to the use of viral vaccines: influenza. Review of influenza activity-2002. S Afr Med J 2003, 93:271.
8. Frank A.L., Taber L.H., Wells C.R., Wells J.M., Glezen W.P., Paredes A. Patterns of shedding of myxoviruses and paramyxoviruses in children. J Infect Dis 1981, 144:433-441.
9. Ohmit S.E., Victor J.C., Teich E.R., Truscon R.K., Rotthoff J.R., Newton D.W., et al. Prevention of symptomatic seasonal influenza in 2005-2006 by inactivated and live attenuated vaccines. J Infect Dis 2008, 198:312-317.
10. Beran J., Wertzova V., Honegr K., Kaliskova E., Havlickova M., Havlik J., et al. Challenge of conducting a placebo-controlled randomized efficacy study for influenza vaccine in a season with low attack rate and a mismatched vaccine B strain: a concrete example. BMC Infect Dis 2009, 9:2.
11. Belshe R.B., Coelingh K., Ambrose C.S., Woo J.C., Wu X. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity. Vaccine 2010, 28:2149-2156.
12. Ambrose C.S., Levin M.J., Belshe R.B. The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults. Influenza Other Respir Viruses 2010, 5:67-75.
13. Treanor J.J., Kotloff K., Betts R.F., Belshe R., Newman F., Iacuzio D., et al. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 1999, 18:899-906.
14. Govaert T.M., Dinant G.J., Aretz K., Masurel N., Sprenger M.J., Knottnerus J.A. Adverse reactions to influenza vaccine in elderly people: randomised double blind placebo controlled trial. BMJ 1993, 307:988-990.
15. Margolis K.L., Nichol K.L., Poland G.A., Pluhar R.E. Frequency of adverse reactions to influenza vaccine in the elderly. A randomized, placebo-controlled trial. JAMA 1990, 264:1139-1141.
16. Falsey A.R., Treanor J.J., Tornieporth N., Capellan J., Gorse G.J. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis 2009, 200:172-180.
17. van Vuuren A., Rheeder P., Hak E. Effectiveness of influenza vaccination in the elderly in South Africa. Epidemiol Infect 2008, 1-9.